Form 4: Astria Therapeutics Director Kenneth Bate Acquires Stock Options
SEC Form 4 Filing
Director Kenneth Bate of Astria Therapeutics, Inc. reports the acquisition of stock options on June 5, 2024.
Summary
- Kenneth Bate, a director of Astria Therapeutics, Inc., filed a Form 4 on June 6, 2024, reporting a transaction.
- On June 5, 2024, Bate acquired 14,100 stock options with an exercise price of $9.18.
- These options vest on June 4, 2034, one year from the grant date, contingent upon continued service as a director.
- Following the reported transaction, Bate directly owns 14,100 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock option grant |
| 06/04/2034 | Stock options vest date |
| 06/06/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.